Table 1 Patient characteristics in MR and multi-modality cohorts
Characteristic | MR cohort | Multi-modality cohort | ||
|---|---|---|---|---|
Training set (n = 202) | Test set (n = 87) | Training set (n = 102) | Test set (n = 43) | |
Sex | ||||
 Male | 144 (71.3%) | 65 (74.7%) | 75 (73.5%) | 29 (67.4%) |
 Female | 58 (28.7%) | 22 (25.3%) | 27 (26.5%) | 14 (32.6%) |
Age | ||||
 Median (IQR) | 48 (41–56) | 49 (40–57) | 49 (42–57) | 51 (40–57) |
 ≤ 40 | 50 (24.8%) | 23 (26.4%) | 19 (18.6%) | 12 (27.9%) |
 40–50 | 67 (33.2%) | 48 (55.2%) | 63 (61.8%) | 25 (58.1%) |
 > 50 | 85 (42%) | 16 (18.4%) | 20 (19.6%) | 6 (14.0%) |
T stage | ||||
 T1 | 7 (3.5%) | 1 (1.2%) | 3 (2.9%) | 0 (0.0%) |
 T2 | 54 (26.7%) | 32 (36.8%) | 29 (28.4%) | 6 (14.0%) |
 T3 | 84 (41.6%) | 25 (28.7%) | 48 (47.1%) | 20 (46.5%) |
 T4 | 57 (28.2%) | 29 (33.3%) | 22 (21.6%) | 17 (39.5%) |
N stage | ||||
 N0 | 12 (5.9%) | 6 (6.9%) | 8 (7.8%) | 1 (2.3%) |
 N1 | 49 (24.3%) | 23 (26.4%) | 28 (27.5%) | 8 (18.6%) |
 N2 | 106 (52.5%) | 47 (54.0%) | 48 (47.1%) | 19 (44.2%) |
 N3 | 35 (17.3%) | 11 (12.7%) | 18 (17.6%) | 15 (34.9%) |
M stage | ||||
 M0 | 199 (98.5%) | 84 (96.6%) | 100 (98.0%) | 42 (97.7%) |
 M1 | 3 (1.5%) | 3 (3.4%) | 2 (2.0%) | 1 (2.3%) |
Overall stage | ||||
 I | 2 (1.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
 II | 18 (8.9%) | 14 (16.1%) | 11 (10.8%) | 1 (2.3%) |
 III | 93 (46.0%) | 32 (36.8%) | 57 (55.9%) | 19 (44.2%) |
 IV | 86 (42.6%) | 37 (42.5%) | 34 (33.3%) | 23 (53.5%) |
 V | 3 (1.5%) | 4 (4.6%) | 0 (0.0%) | 0 (0.0%) |
Follow-up time (mo) | ||||
 Median (IQR) | 49 (23–61) | 55 (34–63) | 11 (7–17) | 10 (6–19) |